Notícias

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease vaccine candidate PF-07307405 had its Marketing Authorization Application validated by the European Medicines Agency based on Phase 3 trial data. Together, these vaccine milestones highlight Pfizer’s ongoing role in infectious disease prevention across both seasonal COVID-19 protection and...

Tech firms are courting Democrats and hiring advisers to prepare for potential investigations if Republicans lose control of the House.

The real bet is on what lies beyond this year's performance: a pipeline that could change everything.

By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.

Nvidia shares are rallying on the back of another incredible quarterly earnings report.

Three famous dividend names trade well below their five-year highs while their CEOs publicly draw lines in the sand around the payout. Whether the cash flow actually backs that confidence is a different question entirely.

The oncology franchise that still carries about half of Merck is decelerating while the stock trades near its high.

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

The company now leads with a cost-savings total and a growth rate that does not begin until the end of the decade, which tells a holder far less about whether its medicines are winning.

LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.

Pfizer's payout ratio is above 100%, but that's not the number you should probably be watching right now.

Novo Nordisk (NVO) said Thursday that China's National Medical Products Administration has accepted

Pfizer Inc. (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) offer investors two very different dividend stories. Pfizer (NYSE:PFE) is working to rebuild growth before major patent expirations arrive, while Abbott (NYSE:ABT) is combining a long dividend-growth record with a more diversified healthcare portfolio. Pfizer (NYSE:PFE) may offer turnaround potential, but Abbott’s (NYSE:ABT) latest results present the steadier […]

The drugmaker's stock is on a tear, but for investors arriving now, the real question is whether the business can outrun its own premium price.

While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That drug now represents a small fraction of the Innovative Medicine portfolio. The remaining 96% of that business is posting remarkable growth, expanding at over 14.

These are two stocks that pay investors a regular income.

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

The past year's gain was bought with volume and access, and management has already said net price goes lower from here.

PHP and ARCH have founded Sentivera, a biotech that now has an immunology licensing deal with China-based Haisco.

Pfizer (NYSE:PFE) and Valneva announced that the European Medicines Agency has validated the Marketing Authorization Application for their Lyme disease vaccine candidate, PF-07307405. The validation starts the EMA regulatory assessment process for what could become a first in class Lyme disease vaccine for use in both North America and Europe. The application is supported by Phase 3 efficacy data, with the companies highlighting an unmet medical need in Lyme disease prevention. This move by...

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire post-KEYTRUDA story.

These healthcare leaders are unlikely to suspend their dividend programs.

PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.

Beyond strong drugs, the stock’s ascent was powered by its notable profitability.

Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season.

BBIO's Q2 sales jump 120% as Attruby drives growth, while higher spending widens the loss and raises the stakes for 2026.

BridgeBio's fast-growing Attruby sales and pipeline expansion face a steep valuation premium, continued losses and launch risks.

BridgeBio's 24% three-month rally faces a higher bar as Attruby growth and pipeline catalysts compete with valuation and execution risks.

AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.

Management is betting on a bigger year than ever, but investors seem to be waiting for a catch.